In The News
HWL Ebsworth ex-partner asks High Court to overturn age-related expulsion
Munich Re can bring fresh claims in $700M case against AMP
Lundbeck, Sandoz end long-running Lexapro patent war
Giles George has good case for lien over costs in barrister’s case: judge
NSW loses bid to strike out class action’s ‘amorphous’ exemplary damages claim
Novartis unit sues GenesisCare over cancer treatment patent
ASIC still has ‘grave concerns’ over businessman’s plans amid $35M probe
Origin faces shareholder class action over energy markets guidance
Law firm might drop iPhone class action against Apple, court told
$20M settlement in NAB class action OK’d despite concerns over lawyers’ fees
Please login to bookmark Close

Pharmaceutical giant Lundbeck has resolved its battle with Novartis unit Sandoz over top-selling drug Lexapro, a battle that has raged for years and across multiple courts.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au